1-(2,2-Diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,2-Diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine
• 英文别名: N-[1-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]ethyl]-1-(2,2-diphenylethyl)piperidine-3-carboxamide
• 化学式: C₃₃H₃₅N₅O
• 分子量: 517.674
• InChiKey: LSJWRRKTQHMNJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(4-cyanobenzyl)-1-(2-aminoethyl)-1H-imidazole 、 1-(2,2-Diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine 、 1-(2,2-Diphenylethyl)-3(S)-carboxy piperidine 生成 1-(2,2-Diphenylethyl)-3(S)-[5-(4-cyanobenzyl)-1H-imidazol-1-ylethylcarbamoyl]piperdine
  参考文献：
  名称：

  Inhibitors of farnesyl-protein transferase

  摘要：

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼醇化的化合物。该发明进一步涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras的方法。

  公开号：

  US05817678A1

文献信息

• [EN] MITOTIC KINESIN INHIBITORS<br/>[FR] INHIBITEUR DE KINESINES MITOTIQUES
  申请人：MERCK & CO INC

  公开号：WO2003105855A1

  公开（公告）日：2003-12-24

  The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及对二氢吡咯烷化合物，其用于治疗细胞增殖性疾病，治疗与KSP动力蛋白活性相关的疾病，以及抑制KSP动力蛋白。该发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。
• Active salt forms with tyrosine kinase activity
  申请人：——

  公开号：US20040023978A1

  公开（公告）日：2004-02-05

  The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

  本发明涉及口服活性盐形式的甲磺酸盐，其抑制、调节和/或调控酪氨酸激酶信号传导的4-[2-(5-氰基噻唑-2-基氨基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺，含有这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等哺乳动物。
• Polymorphs with tyrosine kinase activity
  申请人：——

  公开号：US20040023980A1

  公开（公告）日：2004-02-05

  The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

  本发明涉及活性多型体4-[2-(5-氰基噻唑-2-基氨基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺，其抑制、调节和/或调控酪氨酸激酶信号传导，含有这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等在哺乳动物中。
• 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING
  申请人：Sutton C James

  公开号：US20080045528A1

  公开（公告）日：2008-02-21

  Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  苯并噁唑和苯并噻唑化合物及其立体异构体、互变异构体、溶剂合物、氧化物、酯类和前药以及其药学上可接受的盐已被披露。所述化合物的组合物，无论是单独使用还是与至少一种额外治疗剂组合，并与药学上可接受的载体一起使用的用途也已被披露。这些实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或交换反应，治疗或预防癌症，治疗或预防类风湿性关节炎等退行性骨病，以及/或抑制CSF-1R等分子。
• Salt forms with tyrosine kinase activity
  申请人：——

  公开号：US20040023981A1

  公开（公告）日：2004-02-05

  The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

  本发明涉及盐形式的4-[2-(5-氰基噻唑-2-基氨基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺，该盐形式抑制、调节和/或调控酪氨酸激酶信号转导，含有这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等哺乳动物。